Thank you Roka - that was a very comprehensive and informative post.
I did not realise the subtle complexities of the trial - nor the shades of colour that may be revealed by the results.
It does make sense that the company not give info on secondary endpoints if they were inconclusive.
I was also interested in the explanation of the trials "power" and the company's justification for limiting enrollments to 193 patients - it all makes perfect economic sense.
The fact that there are four symptom clusters also means that analysis and release of results may not be as quick as I had formerly hoped.
Thanks again for that info - appreciated.
on a side issue - weird market in BNO yesterday - one minute knockingon teh door of 60c again then slammed back to 55c........
Does not seem like bots but rather an active strategy to stop a break back above 60c resistance level........
Cheers.
Cheers.
BNO Price at posting:
56.5¢ Sentiment: Buy Disclosure: Held